PRME Prime Medicine Inc
Price (delayed)
$1.79
Market cap
$234.78M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.65
Enterprise value
$79.03M
We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime
Highlights
The EPS has grown by 24% YoY and by 20% from the previous quarter
PRME's net income is up by 11% since the previous quarter
The quick ratio has soared by 125% YoY but it has decreased by 17% from the previous quarter
Prime Medicine's equity has decreased by 19% from the previous quarter but it has increased by 15% YoY
PRME's debt has surged by 199% year-on-year
Key stats
What are the main financial stats of PRME
Market
Valuations
Earnings
Shares outstanding
131.16M
Market cap
$234.78M
Enterprise value
$79.03M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.53
Price to sales (P/S)
71.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.49
Revenue
$2.98M
Gross profit
$2.98M
Operating income
-$202.47M
Net income
-$195.88M
EBIT
-$195.88M
EBITDA
-$177.4M
Free cash flow
-$130.16M
Per share
Balance sheet
Liquidity
EPS
-$1.65
EPS diluted
-$1.65
Free cash flow per share
-$1.1
Book value per share
$1.17
Revenue per share
$0.03
TBVPS
$2.51
Total assets
$297.51M
Total liabilities
$144.36M
Debt
$40.79M
Equity
$153.15M
Working capital
$173.93M
Debt to equity
0.27
Current ratio
5.58
Quick ratio
5.39
Net debt/EBITDA
0.88
Margins
Efficiency
Dividend
EBITDA margin
-5,947%
Gross margin
100%
Net margin
-6,566.6%
Operating margin
-6,787.4%
Return on assets
-65.2%
Return on equity
-100.1%
Return on invested capital
-105.5%
Return on capital employed
-75.5%
Return on sales
-6,566.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PRME stock price
How has the Prime Medicine stock price performed over time
Intraday
0.28%
1 week
-8.21%
1 month
-28.97%
1 year
-71.68%
YTD
-38.7%
QTD
-10.05%
Financial performance
How have Prime Medicine's revenue and profit performed over time
Revenue
$2.98M
Gross profit
$2.98M
Operating income
-$202.47M
Net income
-$195.88M
Gross margin
100%
Net margin
-6,566.6%
PRME's net margin has surged by 76% since the previous quarter
The operating margin has surged by 76% since the previous quarter
PRME's net income is up by 11% since the previous quarter
The operating income has grown by 11% from the previous quarter
Growth
What is Prime Medicine's growth rate over time
Valuation
What is Prime Medicine stock price valuation
P/E
N/A
P/B
1.53
P/S
71.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.49
The EPS has grown by 24% YoY and by 20% from the previous quarter
PRME's price to book (P/B) is 47% lower than its last 4 quarters average of 2.9
Prime Medicine's equity has decreased by 19% from the previous quarter but it has increased by 15% YoY
The P/S is 90% below the last 4 quarters average of 742.3
Efficiency
How efficient is Prime Medicine business performance
The ROS has soared by 76% from the previous quarter
The return on invested capital has grown by 24% year-on-year and by 12% since the previous quarter
Prime Medicine's return on assets has increased by 18% QoQ and by 15% YoY
The return on equity has increased by 13% since the previous quarter but it has declined by 7% year-on-year
Dividends
What is PRME's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PRME.
Financial health
How did Prime Medicine financials performed over time
PRME's total assets is 106% greater than its total liabilities
The total liabilities has surged by 138% year-on-year
The quick ratio has soared by 125% YoY but it has decreased by 17% from the previous quarter
PRME's debt is 73% smaller than its equity
PRME's debt has surged by 199% year-on-year
Prime Medicine's debt to equity has surged by 170% YoY and by 23% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.